Brun-Pascaud M, Girard P M, Pocidalo J J
Institut National de la Santé et de la Recherche Médicale, U. 13, Hôpital Claude Bernard, Paris, France.
Antimicrob Agents Chemother. 1992 Oct;36(10):2328-30. doi: 10.1128/AAC.36.10.2328.
Low-dose trimethoprim-sulfamethoxazole (TMP-SMX) alone was found to be as effective as low-dose TMP-SMX plus zidovudine and standard-dose TMP-SMX alone in preventing and treating Pneumocystis carinii pneumonia (PCP) in an immunosuppressed-rat model. Zidovudine alone had no preventive or curative effect on PCP. We conclude that the initially reported reduced incidence of PCP in human immunodeficiency virus-infected patients treated with zidovudine alone is not due to anti-P. carinii activity of zidovudine. Furthermore, the clinical efficacy of low-dose TMP-SMX for the prevention and treatment of PCP should be further investigated.
在免疫抑制大鼠模型中,单独使用低剂量甲氧苄啶-磺胺甲恶唑(TMP-SMX)预防和治疗卡氏肺孢子虫肺炎(PCP),被发现与低剂量TMP-SMX加齐多夫定以及单独使用标准剂量TMP-SMX一样有效。单独使用齐多夫定对PCP没有预防或治疗作用。我们得出结论,最初报道的单独使用齐多夫定治疗的人类免疫缺陷病毒感染患者中PCP发病率降低,并非由于齐多夫定的抗卡氏肺孢子虫活性。此外,低剂量TMP-SMX预防和治疗PCP的临床疗效应进一步研究。